programme of research

University of Bradford

2001/2

YCR Laboratory of Drug Design
The Tom Connors Cancer Research Centre
Director: Professor T.C. Jenkins

T.C. Jenkins
S.L. Moores
NQO2 enzyme-directed strategies for use in ENACT therapy

T.C. Jenkins
L.J. Adams
J.R.P. Arnold
T. Brown
G. Wilkinson
Pyrrolo[2,1-c][1,4]benzodiazepines (PBDs) as DNA-targeting agents


T.C. Jenkins
J.R.P. Arnold
P.J. Perry
T.A. Norris
T. Brown
DNA tetraplex-binding ligands as novel inhibitors of telomerase

P.J. Perry
J.R.P. Arnold
T.C. Jenkins
Activation of p53 response through inhibition of the p53-MDM2 complex


T.C. Jenkins
P.J. Perry
Mutagenic profiling of DNA-interactive anti-cancer drugs


P.J. Perry
T.A. Norris
T.C. Jenkins
Microtubule inhibitors: chalcones as mimics of combretastatin A-4


P.J. Perry
J.R.P. Arnold
T.C. Jenkins
CYP1B1-activated prodrugs in novel anti-cancer therapies


T.C. Jenkins
J.R.P. Arnold
T.A. Norris
P.J. Perry
Novel mRNA-targeted therapeutic agents


J.R.P. Arnold
T.C. Jenkins
Interactions of thymidylate synthase with RNA and clinical anti-tumour agents


J.R.P. Arnold
Antisense nucleic acid systems for therapeutic control


T.C. Jenkins
J.R.P. Arnold
Studies of nucleic acid structure and thermodynamics


J.R.P. Arnold
Development of ribozyme-based anti-cancer therapy